Resmed (RSMDF) Non-Current Deffered Revenue (2010 - 2026)

Resmed (RSMDF) has reported Non-Current Deffered Revenue for 17 consecutive years, with $171.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deffered Revenue rose 9.02% year-over-year to $171.0 million; the trailing twelve-month figure through Jun 2026 stood at $171.0 million (up 9.02% YoY), and the FY2026 full-year result was $171.0 million, up 9.02% from the prior year.
• Non-Current Deffered Revenue climbed to $171.0 million in Q2 2026 per RSMDF's latest filing, from $163.1 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $171.0 million in Q2 2026 and bottomed at $94.1 million in Q1 2022.
• Historically, Non-Current Deffered Revenue has averaged $132.7 million across 5 years, with a median of $134.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue advanced 4.33% in 2022, then gained 24.86% in 2023.
• Over 5 years, Non-Current Deffered Revenue stood at $102.8 million in 2022, then increased by 23.94% to $127.4 million in 2023, then grew by 14.99% to $146.5 million in 2024, then rose by 9.06% to $159.8 million in 2025, then increased by 6.99% to $171.0 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $171.0 million, $163.1 million, and $159.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.